In Brief: Tecnol buys Sparta's wound care business
This article was originally published in The Gray Sheet
Executive Summary
Tecnol buys Sparta's wound care business: Pleasanton, California-based Sparta Surgical sells wound care product line and related Hammonton, New Jersey-based operations to Tecnol Medical Products for approximately $5.7 mil., gaining approximately $5 mil. in cash and a promissory note worth the value of the balance. Sparta's portfolio of wound care products accounted for 52% of FY 1995 (ended Feb. 28) revenues (approximately $3.7 mil.). Sparta says in a Dec. 11 press release that the sale allows it to "concentrate on more profitable product lines, such as microsurgical instruments, critical care disposables, oral maxillofacial plating systems and electrotherapy products"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.